A securities class action lawsuit has been filed on behalf of investors who bought Corcept Therapeutics common stock between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the company misled investors about the strength of clinical evidence and regulatory prospects for its relacorilant new drug application, and says investors were harmed when concerns about FDA approval risk emerged. Investors seeking to be appointed lead plaintiff must file a motion by April 21, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271730PRIMZONEFULLFEED9663221) on February 27, 2026, and is solely responsible for the information contained therein.